Literature DB >> 11170908

Reactivation of human herpesvirus type 6 in multiple organ failure syndrome.

A Desachy1, S Ranger-Rogez, B François, C Venot, I Traccard, H Gastinne, F Denis, P Vignon.   

Abstract

Human herpesvirus type 6 (HHV-6) and cytomegalovirus (CMV) are known to interact with the production of cytokines. In this study, we sought to determine the incidence of HHV-6 and CMV reactivation during multiple organ failure syndrome (MOFS) and to evaluate the potential effects of viral replication on both the morbidity and mortality associated with MOFS. Viral reactivation was assessed by use of specific polymerase chain reaction (PCR) analysis of the serum samples obtained from 48 consecutive patients with MOFS (the MOFS group) and from 48 sex- and age-matched patients with <2 organ failures (the control group). In addition, HHV-6 replication was assessed in 106 blood donors (the normal group). The incidence of HHV-6 replication was higher in the MOFS group than in the control and normal groups (26 [54%] of 48 vs. 7 [15%] of 48 and 5 [5%] of 106, respectively; P<.0001), with apparently no influence on morbidity and mortality rates. In contrast, reactivation of CMV was found in a single patient. Further studies are needed to evaluate the pathogenesis of HHV-6 replication in critically ill patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170908     DOI: 10.1086/318474

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

Review 1.  Impact of cytomegalovirus load on host response to sepsis.

Authors:  Thomas Marandu; Michael Dombek; Charles H Cook
Journal:  Med Microbiol Immunol       Date:  2019-04-11       Impact factor: 3.402

2.  Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically Ill Adults.

Authors:  Paula Lopez Roa; Joshua A Hill; Katharine A Kirby; Wendy M Leisenring; Meei-Li Huang; Tracy K Santo; Keith R Jerome; Michael Boeckh; Ajit P Limaye
Journal:  Crit Care Med       Date:  2015-07       Impact factor: 7.598

3.  High-level human herpesvirus-6 viremia associated with onset of Stevens-Johnson syndrome: report of two cases.

Authors:  Amanda F Peppercorn; Melissa B Miller; David Fitzgerald; David J Weber; Pamela A Groben; Bruce A Cairns
Journal:  J Burn Care Res       Date:  2010 Mar-Apr       Impact factor: 1.845

4.  Significance of herpesvirus 6 in BAL fluid of hematology patients with acute respiratory failure.

Authors:  E Mariotte; D Schnell; C Scieux; F Agbalika; J Legoff; P Ribaud; N Boissel; B Schlemmer; E Azoulay
Journal:  Infection       Date:  2011-05-03       Impact factor: 3.553

Review 5.  CMV in critically ill patients: pathogen or bystander?

Authors:  Ajit P Limaye; Michael Boeckh
Journal:  Rev Med Virol       Date:  2010-11       Impact factor: 6.989

Review 6.  Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges.

Authors:  Charles H Cook; Joanne Trgovcich
Journal:  Antiviral Res       Date:  2011-03-23       Impact factor: 5.970

7.  Broncholaveolar lavage to detect cytomegalovirus infection, latency, and reactivation in immune competent hosts.

Authors:  Sara Mansfield; Varun Dwivedi; Sara Byrd; Joanne Trgovcich; Marion Griessl; Michael Gutknecht; Charles H Cook
Journal:  J Med Virol       Date:  2016-02-02       Impact factor: 2.327

8.  Cytomegalovirus and herpes simplex virus effect on the prognosis of mechanically ventilated patients suspected to have ventilator-associated pneumonia.

Authors:  Yannael Coisel; Sabri Bousbia; Jean-Marie Forel; Sami Hraiech; Bernard Lascola; Antoine Roch; Christine Zandotti; Matthieu Million; Samir Jaber; Didier Raoult; Laurent Papazian
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 9.  Cytomegalovirus infection in critically ill patients: a systematic review.

Authors:  Ryosuke Osawa; Nina Singh
Journal:  Crit Care       Date:  2009-05-14       Impact factor: 9.097

10.  Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.

Authors:  Nicholas J Cowley; Andrew Owen; Sarah C Shiels; Joanne Millar; Rebecca Woolley; Natalie Ives; Husam Osman; Paul Moss; Julian F Bion
Journal:  JAMA Intern Med       Date:  2017-06-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.